Prof Paul Gurbel is board-certified in internal medicine, cardiovascular disease, and interventional cardiology by the American Board of Internal Medicine. He is Professor of Medicine at Johns Hopkins University School of Medicine and Adjunct Professor of Medicine at Duke University School of Medicine. He is the Director of Cardiovascular Research and Interventional Cardiology for the Inova Health System and Director of the Inova Center for Thrombosis Research and Drug Development. His research has focused on defining the effects of antiplatelet agents, antiplatelet agent development, and understanding the relation of platelet reactivity to ischemic event occurrence in patients undergoing stenting. His lab instituted the field of personalized antiplatelet therapy based on phenotypic and genetic analyses.